TherapeuticsMD (TXMD) Finished Goods (2012 - 2022)

TherapeuticsMD's Finished Goods history runs 11 years deep, the most recent figure standing at $4.5 million for Q3 2022.

• Quarterly Finished Goods rose 42.36% year-over-year to $4.5 million in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $4.5 million (up 42.36% YoY) and the FY2021 annual result came in at $2.9 million, down 12.3% from the prior year.
• Finished Goods was $4.5 million for Q3 2022 at TherapeuticsMD, up from $4.0 million in the prior quarter.
• Across five years, Finished Goods topped out at $5.0 million in Q3 2019 and bottomed at $1.6 million in Q1 2018.
• A 5-year average of $3.4 million and a median of $3.3 million in 2019 frame the typical range for Finished Goods.
• Annual changes were most pronounced in 2019 — Finished Goods jumped 122.24% — and 2021, when it tumbled 41.45%.
• TherapeuticsMD's Finished Goods stood at $2.9 million in 2018, then soared by 71.09% to $5.0 million in 2019, then slumped by 32.69% to $3.4 million in 2020, then decreased by 12.3% to $2.9 million in 2021, then jumped by 54.42% to $4.5 million in 2022.
• Business Quant data shows TXMD's Finished Goods at $4.5 million in Q3 2022, $4.0 million in Q2 2022, and $3.3 million in Q1 2022.